A subgroup from a National Institute of Environmental Health Sciences, workshop concerned with characterizing the effects of endocrine disruptors on human health at environmental exposure levels considered the question, If diethylstilbestrol (DES) were introduced into the market for human use today and likely to result in low-dose exposure of the human fetus, what would be required to assess risk? On the basis of an analysis of the quality of data on human DES exposure, the critical times and doses for inducing genital tract malformations and cancer must be determined. This would be facilitated through analysis of the ontogeny of estrogen receptor expression in the developing human genital tract. Models of low-dose estrogenic effects will have to be developed for human and rodent genital tract development. Mouse models offer many advantages over other potential animal models because of the wealth of the earlier literature, the availability of sensitive end points, the availability of mutant lines, and the possibility of generating genetically engineered model systems. Through multidisciplinary approaches, it should be possible to elucidate the cellular and molecular mechanisms of endocrine disruption elicited by estrogens during development and facilitate an assessment of risk to humans. (4, 5) and were thought to cross the placenta in humans (6,7), direct evidence of teratogenicity of estrogens in humans was unknown until after the association between DES and vaginal adenocarcinoma was reported. In any case, despite the tragedy of the DES episode, the human DES clinical data offer an unprecedented opportunity to learn about the consequences of in utero exposure to a potent estrogen and thus to infer potential risks following exposure to less potent environmental estrogens.
This report is the product of a subgroup from a National Institute of Environmental Health Sciences, workshop concerned with characterizing the effects of endocrine disruptors on human health at environmental exposure levels. This workshop provided a forum to discuss methods and data needed to improve risk assessments of endocrine disruptors. This report addresses data on the health effects of diethylstilbestrol (DES) and how this information may be used to evaluate risks from exposure to weaker synthetic estrogens. The goal of this review is a re-evaluation of the risk assessment of the human DES experience, using the abundant experimental animal data to answer the following questions: How can we use the human and animal data to better anticipate adverse health effects from agents that are introduced in the future? How could we have anticipated the consequences of DES exposure from the information available when DES was approved for use in pregnant women? Can general lessons be drawn regarding animal-to-human extrapolation for endocrine disruptors? To answer these questions, a historical perspective is required.
Years before clinical use of DES in pregnant women, estrogens in general, and DES specifically, were known to induce breast cancer in postnatal mice and rats when pharmacologic doses were given chronically over long periods (1) (2) (3) . The relationship of postnatal studies to possible transplacental carcinogenesis was certainly not appreciated in the 1930s and early 1940s. Indeed, transplacental carcinogenesis of DES or other estrogens was not considered or reported by investigators at that time. Although prior to 1945, estrogens were known to perturb urogenital development in fetal rodents (4, 5) and were thought to cross the placenta in humans (6, 7) , direct evidence of teratogenicity of estrogens in humans was unknown until after the association between DES and vaginal adenocarcinoma was reported. In any case, despite the tragedy of the DES episode, the human DES clinical data offer an unprecedented opportunity to learn about the consequences of in utero exposure to a potent estrogen and thus to infer potential risks following exposure to less potent environmental estrogens.
If properly interpreted, lessons from the DES episode may prove invaluable for judging potential effects of compounds that have been or will be identified as potential endocrine disruptors. It will be important, however, to keep in mind the considerable differences in potency between such compounds when inferences are drawn concerning potential effects. For example, the carcinogenicity of DES was identified in a human study including only 8 cases and 32 controls (8) . Normal The existence of cohorts exposed to DES at mean total maternal doses spanning more than an order of magnitude provide an opportunity to study the dose-response characteristics for relatively high-dose DES-induced effects. These data also provide the opportunity to compare human clinical data and dose-response data for DES-induced effects observed in animal studies. As part of the ongoing follow-up of DES-exposed cohorts, substantial numbers of exposed males and females have been studied. Depending on the timing ofexposure and the total maternal DES dose administered, unequivocal (and more readily observed) effects seen in males and females include reproductive tract malformations, impaired reproduction, and vaginal carcinoma (29) (30) (31) (32) (33) . More equivocal effects include decreased sperm count (34) (35) (36) , immune dysfunction (37), alterations in sexual behavior (38) , disturbed menstrual cycles (39) , and testicular cancer (40) . To date, DES-exposed males and females diagnosed with malignant or nonmalignant lesions indude individuals in childhood and puberty, and adults less than 50 years of age. Substantial numbers of males and females in the DES adenosis cohort are just now reaching 50 years of age. This is the age when male and female reproductive tract neoplasias typically begin to occur. Additional follow-up of DES-exposed sons will be essential to establish whether they are at increased risk of testicular or prostate cancer. It is important to note that, in general, women have been more extensively studied than men because of the initial association between in utero DES exposure and vaginal cancer and also because of a greater interaction of women with health care services and providers. Furthermore, women have formed DES support groups and have successfully lobbied the government for studies of the adverse effects of DES.
It should also be noted that some of the adverse effects observed as a consequence of in utero exposure to DES occur against an extremely low background incidence of reproductive tract malformations and vaginal carcinoma. By following the DES-exposed cohorts, it will be challenging to determine if more prevalent conditions (i.e., thyroid effects, breast and prostate cancer, endometriosis, immune dysfunction) or conditions that increase in frequency with age (e.g., declining immune function, endometrial hyperplasia and cancer, ovarian cancer, benign prostatic hyperplasia, prostatic cancer) are increased as a result of in utero exposure to DES. Also, the possibility of third-generation effects has to be considered (41) . Table 3 .
Animal Models Summary ofthe Models
The animal models in which the developmental effects of DES exposure have been studied mainly include the mouse, rat, and hamster. The mouse has been the most extensively studied species, and the size of the data set in mice is superior to those for all other species combined. This extensive body of evidence in the mouse extends back about 50 years. The perinatal DES-treated mouse model correlates remarkably well with the adverse effects observed in both male and female humans exposed in utero to DES. Tables 1 and 2 (25) and 0.01 pglkg/day for the neonatal mouse uterus (20, 21, 23 (50, 51) . The expression of lactoferrin is induced by DES in the uterus prenatally, neonatally, and in adult stages (52) , thus making it a particularly attractive biomarker of DES action in the mouse. Lactoferrin has also been localized to a subset of epithelial cells of the human endometrium and is responsive to estrogen (53 induced teratogenicity and/or carcinogenicity should be explored. Studies on genetic and epigenetic changes associated with DES exposure will also be useful in understanding the mechanism of action of DES and other endocrine-disrupting chemicals.
Collectively, the DES database in humans and rodents is likely to provide a highly relevant yardstick upon which to judge the potential estrogenic effects of compounds identified as environmental estrogens. The combination of known estrogenic potency with dose-response data for potential end points of concern in the mice and humans will be a useful tool for characterizing the effects of endocrine disrupters on human health at environmental exposure levels.
